Sign in

Markus Eckstein

@markuseckstein3.bsky.social
80 followers 13 following 11 posts

Pathologist, Translational Cancer Researcher, Biomarker Enthusiast #advance biology centered cancer care Settled at Surgical and Molecular Pathology, University Hospital Erlangen @FAU Erlangen-Nürnberg

PostsRepliesMedia
Reposted by Markus Eckstein
Rafael Kramann, MD, PhD @rkramann.bsky.social · 05/12/2024
Our new paper: Label-free single cell RNA-sequencing leveraging genetix variability: www.nature.com/articles/s41... 🔥🔥
nature.com
Label-free single-cell RNA multiplexing leveraging genetic variability - Nature Communications
Here the authors establish and benchmark a single cell RNA multiplexing framework that enables simple, yet robust high-throughput multiplexing leveraging single cell nucleotide polymorphisms of patien...
082
Reposted by Markus Eckstein
Niklas Klümper @niklaskluemper.bsky.social · 11/12/2024
Happy to share our study published @JCO_ASCO ! ascopubs.org/doi/full/10.12… ➡️Patients with mUC with NECTIN4 amplifications (app. 25%) show remarkable responses to single-agent EV, with a 96% ORR compared to 32% in non-amplified cases! @ptarantinomd.bsky.social @markuseckstein3.bsky.social
051
Reposted by Markus Eckstein
Todd Morgan, MD @wandering-gu.bsky.social · 05/12/2024
Awesome talk by @joshmeeks.bsky.social on trial design in NMIBC. Huge need to get away from single arm trials. #SUO24
1184
Reposted by Markus Eckstein
Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 06/12/2024
Impressive results: Ph 2 trial: BCG + gemcitabine in BCG-exposed #NMIBC (HG Ta/T1/CIS) ✅ 6 & 12 mo CR: 94% & 81% ✅ 6, 12 & 18 mo HG-RFS: 97%, 85%, 76% ✅ 2 Gr AEs (UTI, pneumonitis). No Gr 4,5 AEs Phase 3 trial vs BCG will follow #SUO24 #BladderCancer @oncodaily.bsky.social
095
Markus Eckstein @markuseckstein3.bsky.social · 11/12/2024
Great review! NECTIN4 is an exciting target. More to come ! #cancer #jcoprecisionmedicine #bladdercancer #guoncology #biomarker
041
Markus Eckstein @markuseckstein3.bsky.social · 11/12/2024
Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase 1b/2 dose-escalation and dose-expansion study www.annalsofoncology.org/article/S092...
030
Reposted by Markus Eckstein
Markus Eckstein @markuseckstein3.bsky.social · 29/11/2024
Nice overview on "Emerging ADCs for platinum-refractory UC" from #BLADDR in Vienna! 🚨 ADCs and small molecules came to stay and will likely advance cancer treatment of multiple cancers significantly !
011
Reposted by Markus Eckstein
Markus Eckstein @markuseckstein3.bsky.social · 29/11/2024
Incredible improvement for patient with microsatellite unstable metastatic colorectal cancer. MSI is a Ferrari ride for cancer evolution, but immunotherapy is the perfect match to stop that ride !!! Don’t think that we will see similar success for other „biomarkers“ soon. nej.md/4eGp1tj
021
Markus Eckstein @markuseckstein3.bsky.social · 29/11/2024
Incredible improvement for patient with microsatellite unstable metastatic colorectal cancer. MSI is a Ferrari ride for cancer evolution, but immunotherapy is the perfect match to stop that ride !!! Don’t think that we will see similar success for other „biomarkers“ soon. nej.md/4eGp1tj
021
Markus Eckstein @markuseckstein3.bsky.social · 29/11/2024
Nice overview on "Emerging ADCs for platinum-refractory UC" from #BLADDR in Vienna! 🚨 ADCs and small molecules came to stay and will likely advance cancer treatment of multiple cancers significantly !
011
Reposted by Markus Eckstein
Markus Eckstein @markuseckstein3.bsky.social · 19/11/2024
The Future of Pathology: 3 Innovations Set to Revolutionize Healthcare 🔥 Pathology is entering a new era, and these groundbreaking advancements are about to transform how we diagnose and treat diseases.
111
Reposted by Markus Eckstein
Markus Eckstein @markuseckstein3.bsky.social · 19/11/2024
Have you ever heard about SDHB deficient renal cell carcinoma 🕵️‍♂️? SDHB-deficient kidney cancer is a rare but highly aggressive tumor, often striking patients at a younger age—typically in their 30s and 40s. 🧬 Linked to hereditary mutations in the SDHB gene, it carries a poor prognosis.
022
Reposted by Markus Eckstein
Markus Eckstein @markuseckstein3.bsky.social · 19/11/2024
2️⃣ Digital Pathology and Remote Consultations Gone are the days of solely relying on glass slides under microscopes. Digital pathology converts these slides into high-resolution images that can be shared instantly across the globe. This enables real-time collaboration among experts.
011
Reposted by Markus Eckstein
Markus Eckstein @markuseckstein3.bsky.social · 19/11/2024
1️⃣ Artificial Intelligence in Diagnostics AI is becoming an indispensable tool for pathologists. Machine learning algorithms can analyze complex medical images with incredible speed and accuracy, detecting anomalies that might be missed by the human eye.
111
Reposted by Markus Eckstein
Markus Eckstein @markuseckstein3.bsky.social · 20/11/2024
Differential diagnosis of abdominal pain
011
Markus Eckstein @markuseckstein3.bsky.social · 20/11/2024
Differential diagnosis of abdominal pain
011
Markus Eckstein @markuseckstein3.bsky.social · 19/11/2024
Have you ever heard about SDHB deficient renal cell carcinoma 🕵️‍♂️? SDHB-deficient kidney cancer is a rare but highly aggressive tumor, often striking patients at a younger age—typically in their 30s and 40s. 🧬 Linked to hereditary mutations in the SDHB gene, it carries a poor prognosis.
022
Markus Eckstein @markuseckstein3.bsky.social · 19/11/2024
The Future of Pathology: 3 Innovations Set to Revolutionize Healthcare 🔥 Pathology is entering a new era, and these groundbreaking advancements are about to transform how we diagnose and treat diseases.
111